Bioeconomy Capital
18
11M
8
1
0.50
- Areas of investment
Summary
The fund has exact preference in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the various public portfolio startups of the fund, we may underline Lumen Bioscience, Inc., Arzeda, Riffyn Among the most popular fund investment industries, there are Life Science, Medical Device. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Bioeconomy Capital, startups are often financed by UK Innovation & Science Seed Fund, Sofinnova Partners, Oreilly AlphaTech Ventures. The meaningful sponsors for the fund in investment in the same round are UK Innovation & Science Seed Fund, Oreilly AlphaTech Ventures, Sofinnova Partners. In the next rounds fund is usually obtained by SOSV, Oreilly AlphaTech Ventures, UK Innovation & Science Seed Fund.
Speaking about the real fund results, this VC is 2 percentage points more often commits exit comparing to other organizations. The top activity for fund was in 2017. The usual things for fund are deals in the range of 5 - 10 millions dollars. The fund is constantly included in less than 2 investment rounds annually.
Investments analytics
Analytics
- Total investments
- 18
- Lead investments
- 1
- Follow on index
- 0.50
- Investments by industry
- Biotechnology (12)
- Life Science (8)
- Pharmaceutical (7)
- Software (4)
- Machine Learning (4) Show 10 more
- Investments by region
-
- United States (14)
- United Kingdom (3)
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 9
- Group Appearance index
- 0.89
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Appwapp | 01 Aug 2012 | Internet, Mobile, Developer Tools, Internet of Things, iOS, Android, Web Hosting, Web Development | Seed | 35K | Quebec, Montréal, Canada |
| Arzeda | 20 Jul 2017 | Biotechnology, Information Technology, Information Services | Early Stage Venture | 12M | United States, Washington, Seattle |
| Emerge Diagnostics | 03 Jul 2014 | Biotechnology, Health Care, Health Diagnostics | Seed | 885K | United States, California, Carlsbad |
| Fleetsmith | 01 Jan 2019 | Enterprise Software, Small and Medium Businesses, Security, IT Management | Early Stage Venture | 0 | United States, California, San Francisco |
| Parse Biosciences | 14 Dec 2023 | Biotechnology, Genetics, Life Science, Bioinformatics | Late Stage Venture | 50M | United States, Washington, Seattle |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.